| |
| |
|
| Insider
Information: |
Altshuler David |
| Relationship: |
EVP, Chief Scientific... |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
25,813 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$11,436,450 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
25,813 |
|
|
| Total
Value |
$11,436,450 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Chief Scientific... |
2024-05-15 |
25,813 |
2014-07-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
157 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-10-22 |
4 |
OE |
$155.57 |
$570,786 |
D/D |
3,669 |
35,222 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-10-22 |
4 |
AS |
$194.37 |
$713,144 |
D/D |
(3,669) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-04 |
4 |
AS |
$200.26 |
$827,049 |
D/D |
(4,126) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-04 |
4 |
OE |
$86.52 |
$365,117 |
D/D |
4,126 |
35,679 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-06 |
4 |
OE |
$155.57 |
$190,262 |
D/D |
1,223 |
32,776 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-06 |
4 |
AS |
$196.08 |
$241,189 |
D/D |
(1,223) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-15 |
4 |
AS |
$205.95 |
$12,357 |
D/D |
(60) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-25 |
4 |
AS |
$219.37 |
$857,737 |
D/D |
(3,910) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-25 |
4 |
OE |
$187.53 |
$733,242 |
D/D |
3,910 |
35,463 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-03 |
4 |
OE |
$86.52 |
$365,117 |
D/D |
4,126 |
35,679 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-03 |
4 |
AS |
$229.35 |
$953,861 |
D/D |
(4,126) |
31,553 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
38,757 |
70,310 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-06 |
4 |
AS |
$238.74 |
$604,775 |
D/D |
(2,526) |
70,310 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-06 |
4 |
OE |
$155.57 |
$434,614 |
D/D |
2,526 |
72,836 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-10 |
4 |
D |
$240.95 |
$3,206,563 |
D/D |
(13,308) |
57,002 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-11 |
4 |
AS |
$243.36 |
$4,191,771 |
D/D |
(17,032) |
39,970 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-17 |
4 |
D |
$241.50 |
$602,784 |
D/D |
(2,496) |
37,474 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-18 |
4 |
AS |
$241.80 |
$762,201 |
D/D |
(3,128) |
34,346 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-24 |
4 |
D |
$239.23 |
$577,980 |
D/D |
(2,416) |
31,930 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-25 |
4 |
AS |
$229.72 |
$706,776 |
D/D |
(3,028) |
28,902 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-05-04 |
4 |
OE |
$86.52 |
$201,592 |
D/D |
2,330 |
31,232 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-05-04 |
4 |
AS |
$259.18 |
$607,803 |
D/D |
(2,330) |
28,902 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-05-06 |
4 |
AS |
$270.20 |
$333,195 |
D/D |
(1,222) |
28,902 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-05-06 |
4 |
OE |
$155.57 |
$190,107 |
D/D |
1,222 |
30,124 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-05-12 |
4 |
OE |
$187.53 |
$244,539 |
D/D |
1,304 |
30,206 |
0 |
- |
|
157 Records found
|
|
Page 4 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
